Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin

1. A method of preparing an oral solid dosage form of at least one pharmaceutically active ingredient consisting of nanoparticles, the process comprising the steps of:

(a) adding the at least one pharmaceutically active ingredient to a solution containing a nanoparticle stabilizer to form a dispersion, wherein the nanoparticle stabilizer is a fish gelatin;

(b) reducing the particle size of the dispersion to form a nanosuspension, wherein no additional nanoparticle stabilizer is added in step (b); and

(c) freeze-drying the nanosuspension of step (b) to form the oral solid dosage form that maintains a pharmaceutically equivalent particle size to the nanosuspension of step (b), wherein no additional nanoparticle stabilizer is added in step (c), and wherein the d50 particle size of the oral solid dosage form is maintained upon extended storage.

2. The method of claim 1 , wherein the fish gelatin is a nongelling, non-hydrolyzed fish gelatin or a combination of multiple non-gelling, nonhydrolyzed fish gelatins.

3. The method of claim 1 , wherein the nanosuspension further comprises at least one pharmaceutical excipient.

4. The method of claim 3 , wherein the at least one pharmaceutical excipient is selected from the group consisting of bulking agents, disintegrants, viscosity modifiers, sweeteners, flavoring agents, coloring agents, pH modifiers, and combinations thereof.

5. The method of claim 1 , wherein the at least one pharmaceutically active ingredient has a measured solubility of less than 1 mg/mL.

6. A freeze-dried, oral solid dosage form of at least one pharmaceutically active ingredient consisting of nanoparticles made by a process comprising the steps of:

(a) adding the at least one pharmaceutically active ingredient to a solution containing a nanoparticle stabilizer to form a dispersion, wherein the nanoparticle stabilizer is a fish gelatin;

(b) reducing the particle size of the dispersion to form a nanosuspension; and

(c) freeze-drying the nanosuspension of step (b), wherein the freeze-dried, oral solid dosage form maintains a pharmaceutically equivalent particle size of less than about 1 micron to the nanosuspension of step (b), wherein no additional nanoparticle stabilizer is added to the nanosuspension, and wherein the d50 particle size of the oral solid dosage form is maintained upon extended storage.

7. The oral solid dosage form of claim 6 , wherein the fish gelatin is a non-gelling, non-hydrolyzed fish gelatin or a combination of multiple non-gelling, non-hydrolyzed fish gelatins.

8. The oral solid dosage form of claim 6 , wherein the nanosuspension further comprises at least one pharmaceutical excipient.

9. The oral solid dosage form of claim 8 , wherein the at least one pharmaceutical excipient is selected from the group consisting of bulking agents, disintegrants, viscosity modifiers, sweeteners, flavoring agents, coloring agents, pH modifiers, and combinations thereof.

10. The oral solid dosage form of claim 6 , wherein the at least one pharmaceutically active ingredient has a measured solubility of less than 1 mg/mL.

11. A freeze-dried, oral solid dosage form consisting essentially of a nanoparticle stabilizer and at least one pharmaceutically active ingredient consisting of nanoparticles;

wherein the nanoparticle stabilizer is fish gelatin,

wherein no additional nanoparticle stabilizer is added to the nanosuspension,

wherein the nanoparticles maintain a pharmaceutically equivalent particle size, and

wherein the d50 particle size of the oral solid dosage form is maintained upon extended storage.

12. The freeze-dried, oral solid dosage form of claim 11 , wherein the fish gelatin is a non-gelling, non-hydrolyzed fish gelatin or a combination of multiple non-gelling, non-hydrolyzed fish gelatins.

13. The freeze-dried, oral solid dosage form of claim 11 , further comprising at least one pharmaceutical excipient.

14. The freeze-dried, oral solid dosage form of claim 13 , wherein the at least one pharmaceutical excipient is selected from the group consisting of bulking agents, disintegrants, viscosity modifiers, sweeteners, flavoring agents, coloring agents, pH modifiers, and combinations thereof.

15. The freeze-dried, oral solid dosage form of claim 11 , wherein the at least one pharmaceutically active ingredient has measured solubility of less than 1 mg/mL.

16. The oral solid dosage form of claim 6 , wherein the pharmaceutically active ingredient is present in the dispersion of step (b) in a range of from about 1% to about 50% by weight of the dispersion.

17. The oral solid dosage form of claim 16 , wherein the pharmaceutically active ingredient is present in the dispersion of step (b) in a range of from about 2% to about 45% by weight of the dispersion.

18. The oral solid dosage form of claim 17 , wherein the pharmaceutically active ingredient is present in the dispersion of step (b) in a range of from about 5% to about 40% by weight of the dispersion.

19. A method of preparing an oral solid dosage form of at least one pharmaceutically active ingredient consisting of nanoparticles, the process comprising the steps of:

(a) adding the at least one pharmaceutically active ingredient to a solution containing a nanoparticle stabilizer to form a dispersion, wherein the nanoparticle stabilizer is a fish gelatin;

(b) reducing the particle size of the dispersion to form a nanosuspension, wherein the d50 particle size remains within a ±150 nm range of a reference particle and less than 1 micron, wherein no additional nanoparticle stabilizer is added in step (b); and

(c) freeze-drying the nanosuspension of step (b) to form the oral solid dosage form that maintains a pharmaceutically equivalent particle size to the nanosuspension of step (b), wherein no additional nanoparticle stabilizer is added in step (c), and wherein the d50 particle size of the oral solid dosage form is maintained upon extended storage.